BioAge Labs, Inc. (NasdaqGS: BIOA)
Health Care · Pharmaceuticals · US
$5.94
-6.31% today · +16.3% 1Y
BioAge Labs, Inc. (NasdaqGS: BIOA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $290.99M and employs 61 people.
Over the last twelve months the share price has gained 16.3%, trading between 5.04 and 25.96.
Tweenvest scores BioAge Labs, Inc. across four factors: quality 54/100, value 51/100. Its strongest factor is quality.
BIOA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $290.99M
- Revenue (TTM)
- $10.36M
- P/E
- —
- EPS
- -2.37
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $25.96
- 52-week low
- $5.04
- Avg volume (3M)
- —
- Shares outstanding
- 45.90M
- Employees
- 61
- Next earnings
- —
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- ISIN
- US09077V1008
- Founded
- 2015
- Listed since
- Sep 26, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Hile Bio-Technology Co., Ltd.SHSE: 603718 | $296.48M | CN¥3.06 | -0.97% |
| Aurora Cannabis Inc.TSX: ACB | $295.82M | CA$6.42 | +1.58% |
| Fuji Pharma Co., Ltd.TSE: 4554 | $293.63M | ¥1,780.00 | +3.49% |
| EyePoint, Inc.NasdaqGM: EYPT | $293.12M | $3.30 | -3.09% |
| Lavipharm S.A.ATSE: LAVI | $288.74M | €1.51 | -3.70% |
| Fulcrum Therapeutics, Inc.NasdaqGM: FULC | $287.64M | $3.75 | -0.66% |
| Hua Medicine (Shanghai) Ltd.SEHK: 2552 | $283.77M | HK$2.23 | -4.90% |
| Tiansheng Pharmaceutical Group Co., Ltd.SZSE: 002872 | $283.43M | CN¥5.97 | -3.55% |
Figures last refreshed Oct 11, 2026.